MBC-11 (trisodium)
Product Specifications
UNSPSC Description
MBC-11 trisodium is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. MBC-11 trisodium has the potential for tumor-induced bone disease (TIBD) research[1].
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mbc-11-trisodium-salt.html
Solubility
H2O : 125 mg/mL (ultrasonic)
Smiles
CC(P(O[Na])(O[Na])=O)(P(OP(O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C=CC(N)=NC2=O)O1)=O)(O[Na])=O)O
Molecular Weight
577.15
References & Citations
[1]Reinholz MM, et al. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul;47(1):12-22.|[2]Zinnen SP, et al. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease. Oncologist. 2019 Mar;24(3):303-e102.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-107093A/MBC-11-trisodium-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-107093A/MBC-11-trisodium-salt-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
387877-45-4
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
